SARS-CoV-2 vaccination in IBD: more pros than cons
Ontology highlight
ABSTRACT: Data on the efficacy and safety of SARS-CoV-2 vaccines are now available, but evidence for these vaccines in those who are immunocompromised (including patients with inflammatory bowel diseases) are lacking. As vaccination begins, questions on advantages and disadvantages can be partially addressed using the experience from other vaccines or immune-mediated inflammatory disorders.
SUBMITTER: D’Amico F
PROVIDER: S-EPMC7816748 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA